Source briefing
Template – Application for transfer of marketing authorisation from transferor to transferee, attachment 1 (veterinary)
Template - Application for transfer of marketing authorisation from transferor to transferee, attachment 1 (veterinary)
Read →
Source briefing
Human medicines European public assessment report (EPAR): Padcev, enfortumab vedotin, Date of authorisation: 13/04/2022, Revision: 9, Status: Authorised
Human medicines European public assessment report (EPAR): Padcev, enfortumab vedotin, Date of authorisation: 13/04/2022, Revision: 9, Status: Authorised
Read →Source briefing
EMA and EISMEA boost cooperation to accelerate health innovations
EMA and the European Innovation Council and SMEs Executive Agency (EISMEA) have strengthened their cooperation in support of health innovation in the European Union (EU). Today…, Enabling innovation is central to our public health mission to bring new…
Read →
Source briefing
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 14-16 July 2026
CVMP opinions on veterinary medicinal products The Committee adopted a positive opinion for a marketing authorisation for Bexatil for the reduction of hyperglycaemia in cats…
Read →
Source briefing
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2026
Twelve new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended twelve medicines for approval at its July 2026 meeting.The committee…, CHMP statistics Key figures from the July 2026 CHMP meeting are represented in the graphic below. © European Medicines…
Read →
Source briefing
Prevention of hepatitis B and C in the European Union and European Economic Area, 2026
This report provides an overview of progress toward the interim targets for elimination for 2025 included in the WHO’s European Regional Action Plan.
Read →Source briefing
Progress in the prevention of vertical transmission of viral hepatitis B in the EU/EEA
Transmission of hepatitis B virus (HBV) from a mother to a child (also referred to as vertical transmission), is low in EU/EEA countries, with few cases attributed to this route among acute notifications.
Read →Source briefing
Euro-GASP external quality assessment scheme for Neisseria gonorrhoeae antimicrobial susceptibility testing – 2025
The 2025 Euro-GASP EQA scheme results confirm that participating laboratories continue to demonstrate a high level of competency in the recovery and susceptibility testing of N. gonorrhoeae. With 27 countries participating and universal adherence to EUCAST guidelines, the…
Read →
Source briefing
World Hepatitis Day 2026: Despite progress towards eliminating hepatitis in Europe, gaps in prevention measures keep 2030 targets out of reach
While Europe has made steady progress in preventing hepatitis B and C the region is set to miss the 2030 target to eliminate viral hepatitis as a public health threat.
Read →Source briefing
World Hepatitis Day 2026: Ensuring that life-saving interventions are accessible to everyone who needs them is a common challenge
World Hepatitis Day is an opportunity to raise awareness of the risk of contracting hepatitis and the health threats it can bring, while at the same time recognising the progress Europe has made to strengthen prevention.
Read →